Provisc 1%

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Provisc 1%

Property Description
Active ingredient Sodium Hyaluronate (1%)
Form Sterile Viscoelastic Solution
Pharmacological class Ophthalmic Viscoelastic Agent
Common use Surgical aid for intraocular procedures
Manufacturer Alcon (Multinational)

What Type of Ophthalmic Product is Provisc 1%?

Provisc 1% is a brand-name Ophthalmic Viscosurgical Device (OVD) manufactured by Alcon. It is classified as an Ophthalmic Viscoelastic Agent—a pharmacological class defined by its ability to exhibit both fluid-like and solid-like properties. Its formulation, a sterile viscoelastic solution specifically engineered for intraocular use, makes it a prescription-only product administered exclusively by ophthalmic surgeons.

What is the Active Ingredient in Provisc 1%?

The functional active ingredient in Provisc 1% is Sodium Hyaluronate at a 1% concentration. This polysaccharide derivative is a naturally occurring biopolymer that is manufactured to a high purity and specific high molecular weight critical for its performance. The biocompatibility of Sodium Hyaluronate is a key advantage that supports its use in sensitive ocular areas. This particular formulation provides an effective balance between viscosity and elasticity among OVDs.

What is the General Purpose of Provisc 1% in Surgery?

The general purpose of Provisc 1% is to facilitate a safer and more controlled surgical environment during procedures like Cataract Extraction and Intraocular Lens (IOL) Implantation. The product’s function is physical and supportive: it is primarily used to provide tissue stabilization, create space within the eye's anterior chamber, and offer essential endothelial protection. Its use is standard practice in microsurgery where its viscoelasticity acts as a temporary internal cushion and scaffolding.

What side effects are possible with Provisc 1%?

Possible Side Effects and Safety Information

The safety profile of Provisc 1% is strictly defined by the adverse reactions documented in official government regulatory materials for ophthalmic viscoelastic agents. These effects are primarily confined to the Eye Disorders System-Organ Class, reflecting its use as an intraocular surgical aid.


Documented Adverse Reactions

Classification Adverse Reaction Example Safety Context
Anticipated Pattern Transient increase in intraocular pressure (IOP) Occurs in the immediate postoperative period and is a key time-related safety note documented by the FDA.
Rare/Serious Corneal edema or Corneal Decompensation These are documented in regulatory labeling as rare but serious ocular complications.
Postoperative Postoperative inflammatory reactions (e.g., iritis) Reported events associated with the use of ophthalmic viscoelastics.

Population and Safety Constraints

The most noted safety pattern is the transient increase in IOP, and regulatory documents specify that patients with pre-existing glaucoma are at an elevated risk for this event following the procedure.

Regulatory safety limitations include contraindication for individuals with a known hypersensitivity to sodium hyaluronate. Furthermore, the official safety notes emphasize the need for careful postoperative monitoring of intraocular pressure to manage this time-dependent safety pattern.

Overdose and Emergency Response

Overdose and When to Seek Help

The official overdose profile for Provisc 1% (Sodium Hyaluronate Ophthalmic Viscoelastic Agent) is derived from its surgical use and is defined by the consequences of excessive retention or over-implantation of the product in the anterior chamber of the eye, not by systemic toxicity. Regulatory guidance emphasizes managing localized effects from retained material.


Documented Overdose Manifestations and Actions

Domain Official Regulatory Statement
Documented Manifestations Transient postoperative elevation of Intraocular Pressure (IOP), Ocular inflammation (iritis/hypopyon), Corneal edema, Ocular pain.
Severe Outcomes Significant and prolonged Intraocular Pressure elevation, which may potentially lead to vision loss if uncontrolled.
Emergency Actions Required Seek immediate medical attention if experiencing severe eye pain, acute vision changes, or signs of severe eye irritation post-procedure.
Supportive Management Management is restricted to symptomatic and supportive treatment, including the use of ocular hypotensive agents to control elevated pressure.

The regulatory documentation explicitly states that no specific antidote is known for this Ophthalmic Viscosurgical Device. The overdose profile is constrained by its nature as a surgical aid, focusing on the localized physical effects. Patients with pre-existing glaucoma may be at increased risk for sustained postoperative IOP rises.

Therapeutic Uses of Provisc 1%

What Provisc 1% Treats: Main Uses and Benefits

The therapeutic domains of Provisc 1% are generally focused on its use as a surgical aid during ophthalmic procedures, rather than as a general treatment for eye diseases or symptoms. The medication is considered relevant in conditions involving surgical intervention.

The therapeutic category relevant to Provisc 1% is associated with use as a surgical aid in anterior segment procedures, including cataract extraction and the implantation of an intraocular lens (IOL). This application is relevant in contexts involving heightened systemic burden where the maintenance of working space is important.

Supportive Benefits and Symptom Management

Provisc 1% is applied in clinical settings that involve acute structural challenges during surgery. It is commonly used to support the patient during difficult episodes where structural challenges are a concern. This use may assist with managing structural challenges associated with surgical intervention and is relevant in contexts involving heightened physiological stress to sensitive ocular tissues.


Quick Fact: Relief for Post-Surgical Discomfort

Provisc 1% is applied in clinical settings that involve acute structural challenges during surgery, which assists with maintaining functional stability and is relevant for easing symptoms that interfere with daily comfort.


Eligibility and Restrictions for Use

Who Can and Cannot Use Provisc 1% — Official Regulatory Information

Official regulatory documentation strictly defines the populations who are eligible or excluded from using Provisc 1%, which is classified as an Ophthalmic Viscosurgical Device.

Contraindications and Established Use

Classification Regulatory Statement
Absolute Contraindication Patients with known hypersensitivity or allergy to sodium hyaluronate or any component of the Provisc 1% preparation must not use the product.
Established Use The device is established for use in adult and older adult patients undergoing procedures like cataract extraction and intraocular lens (IOL) implantation.

Populations Requiring Special Consideration

Use requires special consideration and close monitoring for populations susceptible to postoperative intraocular pressure (IOP) increases, which includes patients with pre-existing ocular conditions such as glaucoma.

Use Not Established

Safety and effectiveness have not been established in the pediatric population. Additionally, the official labeling does not establish safety for use in pregnant or lactating patients. Due to its localized application, no specific restrictions are documented regarding systemic organ function, such as hepatic or renal impairment.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Provisc 1% (Sodium Hyaluronate 1%) is an Ophthalmic Viscoelastic Agent. Its official regulatory interaction profile is defined by local chemical-physical incompatibility and is characterized by the absence of documented systemic interactions.


Documented Physical Incompatibility

The single interaction pattern documented in official labeling is a local chemical incompatibility that mandates a procedural restriction. Co-administration with cationic agents is classified as a contraindicated combination in the presence of the substance. These agents, which include antiseptic solutions or disinfectants containing quaternary ammonium salts (such as Benzalkonium Chloride), are prohibited. The interaction causes the high molecular weight sodium hyaluronate to precipitate or lose its essential viscoelastic function within the surgical field, an outcome documented in regulatory sources.


Absence of Systemic Interactions

The regulatory interaction structure for this product contains no specific warnings regarding systemic drug–drug, drug–food, or metabolic interactions. Official documents do not specify interactions involving CYP450 enzyme inhibition or induction, drug transporter systems, or any exposure-modifying effects on the drug's plasma concentration. Furthermore, there are no documented interactions with food, alcohol, herbal products, or supplements. No mandatory timing-based separation rules or population-specific interaction cautions are documented in the official regulatory prescribing information.

Mechanism of Action

How Provisc 1% Works

The mechanism of Provisc 1% (Sodium Hyaluronate) is unique among ophthalmic agents, relying entirely on its physical-mechanical properties as an Ophthalmic Viscosurgical Device (OVD), rather than biochemical signaling. The high molecular weight solution exerts its action through two primary domains:


️ Viscoelastic Scaffolding and Space Maintenance

This mechanism involves the high viscosity and elasticity of the Sodium Hyaluronate polymer, which physically interacts with the anterior chamber space and intraocular tissues. The solution resists deformation and flow, creating a cohesive, temporary scaffolding that maintains tissue separation. This action contributes to reducing mechanical stress and maintaining the spatial separation of intraocular structures within the eye's anterior segment.


️ Endothelial Protection and Hydrodynamic Modulation

The elastic, cohesive bulk of the agent forms a direct physical barrier to the corneal endothelium, interposing a structure between this sensitive cellular layer and surgical instruments or turbulent fluid dynamics. Furthermore, the high viscosity provides hydrodynamic modulation by physically impeding and dampening rapid fluid movements (surge) within the eye. This effect promotes the physical protection of the corneal endothelium and modulates the ocular environment's response to sudden pressure fluctuations.

Dosage and Administration Information

Provisc 1% (sodium hyaluronate) is an Ophthalmic Viscosurgical Device (OVD) indicated for use as a surgical aid in the anterior segment of the eye, typically during cataract extraction and intraocular lens (IOL) implantation. This product is intended for intraocular use only and must be administered by a qualified ophthalmic surgeon following sterile techniques.


Preparation and Instillation

  1. Temperature: The refrigerated Provisc syringe should be allowed to reach room temperature (approximately 20–40 minutes) prior to use.
  2. Technique: The syringe is designed solely for the injection of the viscous device; it should not be used for aspiration. A sterile, disposable cannula (such as the provided 27-gauge, blunt-tip cannula) is used for slow and careful instillation into the anterior chamber.
  3. Application: The surgeon injects a sufficient amount of Provisc to maintain the anterior chamber depth and protect the intraocular tissues, such as the corneal endothelium. This is typically performed prior to IOL implantation but may be done before or after crystalline lens removal. Provisc may also be used to coat surgical instruments and the IOL prior to insertion.

Post-Operative Removal and Precautions

  • Removal: At the conclusion of the surgical procedure, it is generally recommended that Provisc be removed from the eye as completely as practical. This is done via thorough irrigation using a sterile irrigating solution and aspiration.
  • Monitoring: Since post-operative increases in intraocular pressure (IOP) have been reported with sodium hyaluronate products, the patient's IOP must be carefully monitored after surgery, and appropriate therapy instituted if significant increases occur.
  • Storage: The product must be stored in a refrigerator (2°–8°C or 36°–46°F) and protected from freezing and light.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Summary of Core Research

Research has explored whether Provisc 1% (a cohesive ophthalmic viscosurgical device, or OVD) has been utilized in studies evaluating its role as a surgical aid during anterior segment procedures, primarily cataract extraction and intraocular lens (IOL) implantation.

Studies primarily involved adult participants undergoing non-complicated cataract surgery. The OVD is investigated for its function in maintaining surgical space within the anterior chamber and for providing a layer of protection to intraocular tissues.

Key Findings from Clinical Trials

Endothelial Cell Density (ECD) and IOP

Studies assessed changes in endothelial cell density (ECD) post-surgery, which is a key measure of corneal tissue protection. Comparative studies examined ECD loss over a follow-up period, typically 3 months, between Provisc 1% and other OVDs.

Another primary endpoint was the measurement of change in intraocular pressure (IOP). Studies examined the incidence of transient postoperative IOP increases (spikes), which are common with OVD use, comparing Provisc 1% to placebo or alternative devices.

Combination and Comparative Studies

Studies explored the comparative effects of Provisc 1% when used alone versus in a dual-viscoelastic system (such as the soft-shell technique) alongside a dispersive OVD. Findings regarding the precise outcomes of combination use were examined across different study designs.

The analysis of side effects reported that the most common adverse events related to OVD use were transient IOP increases, mild to moderate postoperative inflammation, and corneal edema. No serious adverse events were consistently deemed related specifically to the study drug.

It is not appropriate to interpret findings as advice or recommendation. Consult with a healthcare professional regarding all medical decisions.

Frequently Asked Questions (FAQ)

Common questions about Provisc 1% (FAQ)


Q: What is the difference between Provisc 1% and other eye drops?

Provisc 1% is officially classified as an Ophthalmic Viscosurgical Device (OVD) and is intended primarily for intraocular surgical use within the eye's anterior chamber. Unlike typical eye drops, which are applied topically, this device is used by a surgeon during procedures like cataract extraction.


Q: Is Provisc 1% used for conditions other than cataract surgery?

Official labeling specifies that the device is intended strictly as a surgical aid during cataract extraction and intraocular lens (IOL) implantation. No other conditions are listed as established indications in official regulatory documentation.


Q: Can Provisc 1% be used in combination with other ocular products?

The product label includes a contraindication (a specific caution against use) for combining Provisc 1% with antiseptic solutions containing cationic agents like quaternary ammonium salts. This is due to a known chemical incompatibility that can cause the high molecular weight sodium hyaluronate to precipitate or lose its essential viscoelastic function.


Q: Is Provisc 1% used for glaucoma?

Provisc 1% is not indicated for the treatment of glaucoma. Regulatory documents note that patients who already have glaucoma should be monitored especially carefully after the procedure, as they are at an elevated risk for a post-operative increase in intraocular pressure (IOP).


Q: How long does the effect of Provisc 1% typically last?

The surgeon removes Provisc 1% from the eye at the end of the procedure. Any small remaining amounts of the active ingredient, sodium hyaluronate, are eliminated naturally by the eye’s clearance system, known as the Canal of Schlemm, with clearance generally described as occurring within hours following surgical removal.


Q: Is Provisc 1% a steroid?

No, Provisc 1% is not a steroid. It is classified as an Ophthalmic Viscoelastic Agent—a substance that has both fluid-like (viscous) and solid-like (elastic) properties—and an Ophthalmic Viscosurgical Device (OVD).


Q: Why is Provisc 1% only available by prescription?

Provisc 1% is restricted to prescription-only use because it is designed primarily for intraocular use, meaning it is injected into the eye itself. Regulatory requirements mandate that it must only be administered by a qualified ophthalmic surgeon following sterile techniques.


Q: Has Provisc 1% been on the market for a long time?

Yes, Provisc 1% has a long-standing regulatory history. Records indicate the device received its original Pre-Market Approval from the FDA dating back to the late 1980s, reflecting an established and lengthy period of regulatory authorization and use.


Q: Does Provisc 1% contain preservatives?

According to the official composition listed in regulatory documentation, the formulation of Provisc 1% is a sterile viscoelastic solution that does not include preservatives among its excipients.


Q: What should I tell my doctor about before using Provisc 1%?

Regulatory documents note that patients should disclose any known hypersensitivity or allergy to sodium hyaluronate or any component of the product. Additionally, pre-existing ocular conditions, especially glaucoma, should be disclosed due to the risk of post-operative intraocular pressure increase.


Q: Can Provisc 1% cause headaches?

While headaches are not specifically listed as a primary ocular side effect of Provisc 1%, general adverse event reports for sodium hyaluronate products used in other medical procedures may include headache.


Q: How often are people typically treated with Provisc 1%?

Provisc 1% is officially designated as a single-use device that is administered once during the surgical procedure for which it is indicated, such as cataract surgery. It is not intended for repeated or multiple administrations.


Q: Is Provisc 1% the same as hyaluronic acid injections?

Provisc 1% is a specific formulation of sodium hyaluronate, but it is intended only for intraocular surgical use with strict regulatory indications. It is not the same product as other hyaluronic acid injections, such as those used for dermal fillers or to treat joint conditions, which have different formulations and regulatory approvals.


Q: Can Provisc 1% be given to older adults?

Yes, the regulatory established use for Provisc 1% includes adult and older adult patients undergoing the indicated procedures, such as cataract extraction and IOL implantation.


Q: Where does Provisc 1% come from (manufacturer)?

Official documentation and regulatory labeling identify the manufacturer of Provisc 1% as Alcon.


Q: What are the known severe side effects of Provisc 1%?

Rare but serious ocular adverse reactions documented in the official regulatory labeling include complications such as corneal edema (swelling of the clear front layer of the eye) and corneal decompensation.


Q: Are there similar products with different concentrations?

Provisc 1% belongs to the class of Ophthalmic Viscosurgical Devices (OVDs). Regulatory summaries acknowledge the existence of other OVD products that may contain different concentrations of sodium hyaluronate or combine it with other viscoelastic substances.


Q: Is Provisc 1% used only in humans?

Yes, the regulatory approval and indications for Provisc 1% are strictly for use as an ophthalmic surgical aid in the anterior segment of the human eye.


Q: Is there a generic version of Provisc 1% available?

Provisc 1% is classified as a specific brand-name device. While other sodium hyaluronate OVD products are available, a direct generic equivalent for the branded Provisc 1% is not explicitly listed in regulatory documentation.


Q: How does the structure of Provisc 1% relate to its function in the eye?

Official documentation explains that the function of Provisc 1%—which is to provide space maintenance and tissue stabilization—is directly related to its specific formulation. These actions are enabled by the ingredient's high molecular weight and its inherent viscoelastic and elastic properties.


Q: Does Provisc 1% contain animal products?

Regulatory descriptions of the sodium hyaluronate active ingredient indicate that it is a highly purified fraction derived through a controlled bacterial fermentation process, rather than being sourced from animal tissue.

How should Provisc 1% be stored and disposed of?

How to Store and Dispose of Provisc Ophthalmic Viscosurgical Device

Provisc (1% Sodium Hyaluronate) must be stored under controlled conditions as defined by regulatory labeling to maintain its sterility and stability.


Storage Requirements

Condition Requirement
Temperature Store in a refrigerator between 2°C and 8°C (36°F and 46°F).
Protection Must be protected from freezing and protected from light.
Packaging Keep in the original carton until use; do not use if the package is opened or damaged.

Handling and Disposal

As an officially designated single-use device, the product must be allowed to reach room temperature before use in a procedure. The used syringe and any unused material must be disposed of following applicable safe disposal procedures and in strict accordance with all local and national regulations for biohazardous materials.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Provisc 1% found in:

A-Z Index: